4.5 Article

2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein-protein interactions

出版社

OXFORD UNIV PRESS
DOI: 10.1093/database/baw007

关键词

-

资金

  1. ANR [ANR-15-CE18-0023-01]
  2. Agence Nationale de la Recherche (ANR) [ANR-15-CE18-0023] Funding Source: Agence Nationale de la Recherche (ANR)

向作者/读者索取更多资源

2P2Idb is a hand-curated structural database dedicated to protein-protein interactions with known small molecule orthosteric modulators. It compiles the structural information related to orthosteric inhibitors and their target [i.e. related 3D structures available in the RCSB Protein Data Bank (PDB)] and provides links to other useful databases. 2P2Idb includes all interactions for which both the protein-protein and protein-inhibitor complexes have been structurally characterized. Since its first release in 2010, the database has grown constantly and the current version contains 27 protein-protein complexes and 274 protein-inhibitor complexes corresponding to 242 unique small molecule inhibitors which represent almost a 5-fold increase compared to the previous version. A number of new data have been added, including new protein-protein complexes, binding affinities, molecular descriptors, precalculated interface parameters and links to other webservers. A new query tool has been implemented to search for inhibitors within the database using standard molecular descriptors. A novel version of the 2P2I-inspector tool has been implemented to calculate a series of physical and chemical parameters of the protein interfaces. Several geometrical parameters including planarity, eccentricity and circularity have been added as well as customizable distance cutoffs. This tool has also been extended to protein-ligand interfaces. The 2P2I database thus represents a wealth of structural source of information for scientists interested in the properties of protein-protein interactions and the design of protein-protein interaction modulators. Database URL: http://2p2idb.cnrs-mrs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Fr-PPIChem: An Academic Compound Library Dedicated to Protein- Protein Interactions

Nicolas Bosc, Christophe Muller, Laurent Hoffer, David Lagorce, Stephane Bourg, Carine Derviaux, Marie-Edith Gourdel, Jean-Christophe Rain, Thomas W. Miller, Bruno O. Villoutreix, Maria Miteva, Pascal Bonnet, Xavier Morelli, Olivier Sperandio, Philippe Roche

ACS CHEMICAL BIOLOGY (2020)

Article Medicine, Research & Experimental

Role in oncology and targeting of the PTK7 tyrosine kinase receptor

Laetitia Ganier, Xavier Morelli, Jean-Paul Borg

M S-MEDECINE SCIENCES (2020)

Article Oncology

In silicomolecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

Jeremy Ariey-Bonnet, Kendall Carrasco, Marion Le Grand, Laurent Hoffer, Stephane Betzi, Mikael Feracci, Philipp Tsvetkov, Francois Devred, Yves Collette, Xavier Morelli, Pedro Ballester, Eddy Pasquier

MOLECULAR ONCOLOGY (2020)

Article Cell Biology

Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo

R. Leblanc, R. Kashyap, K. Barral, A. L. Egea-Jimenez, D. Kovalskyy, M. Feracci, M. Garcia, C. Derviaux, S. Betzi, R. Ghossoub, M. Platonov, P. Roche, X. Morelli, L. Hoffer, Pascale Zimmermann

JOURNAL OF EXTRACELLULAR VESICLES (2020)

Review Cell Biology

The NANOTUMOR consortium - Towards the Tumor Cell Atlas

Florent Colin, Kristine Schauer, Ali Hamiche, Pierre Martineau, Jean-Paul Borg, Jan Bednar, Giulia Bertolin, Luc Camoin, Yves Collette, Stephan Dimitrov, Isabelle Fournier, Vincent Hyenne, Marco A. Mendoza-Parra, Xavier Morelli, Philippe Ronde, Izabela Sumara, Marc Tramier, Patrick Schultz, Jacky G. Goetz

Summary: Cancer is a multi-step disease involving genetic, epigenetic, and environmental factors, as well as complex interactions between malignant and non-malignant cells in the tumour microenvironment. Deciphering the molecular complexes and cellular processes at play is crucial for effectively treating cancer and identifying new therapeutic targets.

BIOLOGY OF THE CELL (2021)

Article Biochemistry & Molecular Biology

Synergy and allostery in ligand binding by HIV-1 Nef

Abdullah Aldehaiman, Afaque A. Momin, Audrey Restouin, Luyao Wang, Xiaoli Shi, Safia Aljedani, Sandrine Opi, Adrien Lugari, Umar F. Shahul Hameed, Luc Ponchon, Xavier Morelli, Mingdong Huang, Christian Dumas, Yves Collette, Stefan T. Arold

Summary: The Nef protein enhances viral pathogenicity by interacting with host cell proteins. Its polyvalency and binding selectivity enable it to disrupt host cell functions, particularly by tightly binding to Src family kinases' SH3 domains. Nef's flexible regions and core domain can allosterically influence ligand selection, promoting coherent protein ensembles. Only a small percentage of human proteins show Nef-like SH3 selectivity, mainly through canonical linear interactions.

BIOCHEMICAL JOURNAL (2021)

Article Chemistry, Medicinal

Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline/Thioridazine

Florian Malard, Eric Jacquet, Naima Nhiri, Christina Sizun, Amelie Chabrier, Samir Messaoudi, Jerome Dejeu, Stephane Betzi, Xu Zhang, Aurelien Thureau, Ewen Lescop

Summary: TCTP protein is a pharmacological target in cancer, and its interactions with drugs such as sertraline and thioridazine have been explored using multiple techniques. The study revealed weaker drug binding compared to previous reports and found that phosphorylation at S46 does not enhance the interaction between TCTP and sertraline. Alternative modes of action for the drugs in tumor cells are discussed in light of these findings.

CHEMMEDCHEM (2022)

Article Microbiology

Inhibiting Type VI Secretion System Activity with a Biomimetic Peptide Designed To Target the Baseplate Wedge Complex

Y. Cherrak, I. Filella-Merce, V. Schmidt, D. Byrne, V. Sgoluppi, R. Chaiaheloudjou, S. Betzi, X. Morelli, M. Nilges, R. Pellarin, E. Durand

Summary: The increasing drug-resistance of bacterial infections poses a threat to human health. Targeting the T6SS virulence factor as a potential strategy to combat pathogens, particularly antibiotic-resistant species, is a promising approach. The development of T6SS inhibitors could provide new therapeutic options to fight drug-resistant infections.
Article Chemistry, Medicinal

Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread

Manon Garcia, Laurent Hoffer, Raphael Leblanc, Fatiha Benmansour, Mikael Feracci, Carine Derviaux, Antonio Luis Egea-Jimenez, Philippe Roche, Pascale Zimmermann, Xavier Morelli, Karine Barral

Summary: Syntenin stimulates exosome production and is implicated in cancer metastasis. Through fragment-based drug design, novel inhibitors targeting syntenin-syndecan interactions were developed. Optimization of a fragment led to the discovery of compounds that selectively affect syntenin-exosome release.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Biochemistry & Molecular Biology

Discovery of Small-Molecule Inhibitors of the PTK7/?-Catenin Interaction Targeting the Wnt Signaling Pathway in Colorectal Cancer

Laetitia Ganier, Stephane Betzi, Carine Derviaux, Philippe Roche, Charlotte Dessaux, Christophe Muller, Laurent Hoffer, Xavier Morelli, Jean-Paul Borg

Summary: PTK7 plays a role in the regulation of the Wnt/beta-catenin pathway and is overexpressed in colorectal cancer (CRC). Targeting the interaction between PTK7 and beta-catenin could be a potential therapeutic strategy for inhibiting cell growth dependent on the Wnt signaling pathway. In addition, inhibiting the kinase domain-dependent functions of PTK7 may also be of interest for further therapeutic development.

ACS CHEMICAL BIOLOGY (2022)

Article Chemistry, Medicinal

CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation

Kendall Carrasco, Camille Montersino, Carine Derviaux, Magali Saez-Ayala, Laurent Hoffer, Audrey Restouin, Remy Castellano, Justine Casassa, Philippe Roche, Eddy Pasquier, Sebastien Combes, Xavier Morelli, Yves Collette, Stephane Betzi

Summary: A BDII-selective compound was discovered through screening the Fr-PPIChem chemical library, showing low activity in cell-based assays but the ability to modulate anti-leukemic activity in combination with various drugs in a cell- and context-dependent differential manner.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Chemistry, Medicinal

Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/ Syntenin Protein-Protein Interaction: A Semi-Automated Hit Identification-to-Optimization Approach

Laurent Hoffer, Manon Garcia, Raphael Leblanc, Mikael Feracci, Stephane Betzi, Khaoula Ben Yaala, Avais M. Daulat, Pascale Zimmermann, Philippe Roche, Karine Barral, Xavier Morelli

Summary: To address the challenge of early hit identification and optimization in drug discovery, we created a strategy called DOTS, which combines molecular dynamic simulations, computer-based library design with encoded medicinal chemistry reactions, constrained docking, and automated compound evaluation. We successfully applied the DOTS strategy to a challenging oncology target, syntenin, and created a best-in-class sub-micromolar small molecule inhibitor validated in cancer cell assays. The key to the success of our DOTS approach was the integration of protein conformational sampling during hit identification and synthetic feasibility ranking of the designed compounds during the optimization process. This approach can be widely used for other protein targets with known 3D structures to rapidly identify and optimize compounds as chemical probes and therapeutic candidates.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Biophysics

Crystal structures of human serum albumin in complex with lysophosphatidylcholine

Yu Wang, Zhipu Luo, Xavier Morelli, Peng Xu, Longguang Jiang, Xiaoli Shi, Mingdong Huang

Summary: In this study, the direct binding of lysophospholipids (lysoPLs), specifically LPC, to human serum albumin (HSA) was demonstrated using fluorescence quenching and optical interferometry assays. The crystal structure analysis revealed the binding sites of LPC on HSA and showed that HSA can still bind to LPC in the presence of myristate. These findings provide insights into the role of HSA as a carrier protein for lysoPLs in blood plasma and the structural basis of their binding mechanisms.

BIOPHYSICAL JOURNAL (2023)

暂无数据